Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi Biosciences Approved for Shanghai STAR IPO, a Dual Listing with Hong Kong

publication date: Mar 31, 2020

Shanghai Junshi Biosciences announced it has been approved to list on the Shanghai STAR Exchange. In late 2018, Junshi completed a $394 million IPO in Hong Kong, and the company's shares have climbed about 50% in the 15 months since then. Just after the Hong Kong IPO, Junshi was approved to market Tuoyi, the first China-developed anti-PD-1 drug as a second-line treatment for melanoma. It is the first domestic PD-1 approved in China. Tuoyi produced $110 million in revenues during 2019. More details....

Stock Symbol: (HK: 1877)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here